SLC5A2 and acute kidney injury: In individual CVOTs, AKI risk was either neutral or reduced with SGLT2 inhibitors, and in meta-analyses involving cardiorenal outcome studies, AKI risk was reduced by approximately 25% [7–10, 17, 18].